XLO

WALTHAM, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that, effective September 1, 2026, the company granted non-qualified stock options to purchase 19,865 shares of its common stock to two new employees under Xilio Therapeutics' 2022 Inducement Stock Incentive Plan.

Received FDA clearance of IND application for XTX501, a potential best-in-class bispecific PD-1 / masked IL-2 Advancing IND-enabling studies for potential first-in-class multi-specific, masked T cell engager programs targeting CLDN18.2 and PSMA+STEAP1; IND applications anticipated in the second half of 2027 Cash runway into the first quarter of 2028 expected to support key milestones across pipeline of next generation multi-specific I-O therapies WALTHAM, Mass., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced pipeline progress and business updates and reported financial results for the second quarter ended June 30, 2026.

WALTHAM, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that, effective July 1, 2026, the company granted non-qualified stock options to purchase 107,060 shares of its common stock to three new employees under Xilio Therapeutics' 2022 Inducement Stock Incentive Plan.

WALTHAM, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced the appointment of Ben Harshbarger as chief legal officer.

Oncology innovation is accelerating as AI, immunotherapy and targeted drugs drive growth for cancer-focused biotech and pharma stocks.

Xilio Therapeutics, Inc. (XLO) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.66. This compares to a loss of $2.52 per share a year ago.

On track for planned IND submission in mid-2026 and Phase 1 initiation in the second half of 2026 for XTX501, a potential best-in-class bispecific PD-1 / masked IL-2

WALTHAM, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that, effective May 1, 2026, the company granted a non-qualified stock options to purchase 1,982 shares of its common stock to one new employee under Xilio Therapeutics' 2022 Inducement Stock Incentive Plan.

XTX601 demonstrated protease-dependent, tumor-selective activation and potent anti-tumor activity in multiple preclinical models

WALTHAM, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced the appointment of Cheryl R. Blanchard, Ph.D. to the company's board of directors. The company also announced that Christina Rossi has stepped down from its board of directors, effective April 15, 2026.